Results 261 to 270 of about 49,135 (301)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Annals of Internal Medicine, 2022
BACKGROUND Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.
W. Lau +12 more
semanticscholar +1 more source
BACKGROUND Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.
W. Lau +12 more
semanticscholar +1 more source
BMJ, 2014
Doctors and patients must tread carefully through emerging risks Options for stroke prevention in high risk non-valvular atrial fibrillation have recently broadened with the addition of new oral anticoagulants as an alternative to warfarin, the traditional and effective treatment.
Blake, Charlton, Rita, Redberg
openaire +2 more sources
Doctors and patients must tread carefully through emerging risks Options for stroke prevention in high risk non-valvular atrial fibrillation have recently broadened with the addition of new oral anticoagulants as an alternative to warfarin, the traditional and effective treatment.
Blake, Charlton, Rita, Redberg
openaire +2 more sources
Drugs, 2008
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across a wide dosage range.
Mark, Sanford, Greg L, Plosker
openaire +2 more sources
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across a wide dosage range.
Mark, Sanford, Greg L, Plosker
openaire +2 more sources
International Journal of Stroke, 2020
Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for ...
P. Kermer +72 more
semanticscholar +1 more source
Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for ...
P. Kermer +72 more
semanticscholar +1 more source
2023
Abstract Dabigatran is a direct oral anticoagulant that acts through specific and reversible inhibition of thrombin. It has been developed as a fixed-dose, modern alternative to vitamin K antagonists such as warfarin. Dabigatran does not require frequent blood testing or dose adjustments.
Alexander P. Benz, Stefan H. Hohnloser
openaire +1 more source
Abstract Dabigatran is a direct oral anticoagulant that acts through specific and reversible inhibition of thrombin. It has been developed as a fixed-dose, modern alternative to vitamin K antagonists such as warfarin. Dabigatran does not require frequent blood testing or dose adjustments.
Alexander P. Benz, Stefan H. Hohnloser
openaire +1 more source
Annals of Internal Medicine, 2020
BACKGROUND It is unclear whether anticoagulant type is associated with the risk for osteoporotic fracture, a deleterious complication of anticoagulants among patients with atrial fibrillation (AF).
W. Lau +9 more
semanticscholar +1 more source
BACKGROUND It is unclear whether anticoagulant type is associated with the risk for osteoporotic fracture, a deleterious complication of anticoagulants among patients with atrial fibrillation (AF).
W. Lau +9 more
semanticscholar +1 more source
Gastrointestinal disorders and dabigatran
Scandinavian Journal of Gastroenterology, 2012Anticoagulants play an important role in the prevention and treatment of a variety of acute and chronic thromboembolic disorders such as primary prevention and treatment of venous thromboembolism or prevention of stroke and systemic embolism in atrial fibrillation just to name of few.
Arthur, Hoffman, P R, Galle
openaire +2 more sources
Idarucizumab for dabigatran overdose
Clinical Toxicology, 2016An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis.
Marijke, Peetermans +7 more
openaire +2 more sources